Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept Plus Cyclosporine Versus Cyclosporine Alone for Newly Diagnosed NSAA
NCT06424639Phase 4Withdrawn
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised trial of luspatercept in aplastic anemia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 6 months. Planned start May 2024; status: withdrawn.
02
Drugs
luspatercept
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06424639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424639.